News PeptiDream Inc.

Equities

4587

JP3836750004

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-25 am EDT			5-day change	1st Jan Change
1,596 ^JPY	-1.08%		+5.07%	+7.33%

Mar. 13	Certain Preferred Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	CI
Mar. 13	Certain Stock Options of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Certain Preferred Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Certain Stock Options of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Certain Common Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
PeptiDream to Partake in Bristol Myers' Tender Offer for All RayzeBio Shares	Feb. 15	MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024	Feb. 14	CI
PeptiDream Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Jefferies Adjusts PeptiDream's Price Target to 1,400 Yen From 1,300 Yen, Keeps at Hold	Jan. 24	MT
Linqmed Inc. announced that it has received ¥680 million in funding from a group of investors	Dec. 21	CI
PeptiDream Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 09	CI
PeptiDream : Corporate Presentation（November 2023, English version)(2MB)	Nov. 01	PU
PeptiDream : コーポレート・プレゼンテーション(2023年11月、英語版）(2MB)	Nov. 01	PU
Jefferies Downgrades PeptiDream to Hold From Buy, Adjusts Price Target to 1,300 Yen From 1,600 Yen	23-10-27	MT
PeptiDream and Bristol-Myers Squibb to Explore Alternatives as PDL1 Program Faces Setback	23-10-27	MT
Peptidream Announces Update on PDL1 Program Partnered with Bristol-Myers Squibb Company	23-10-26	CI
Jefferies Upgrades PeptiDream to Buy From Hold, Adjusts Price Target to 1,600 Yen From 1,900 Yen	23-10-18	MT
PeptiDream : Sustainability Report 2023(2.9 MB)	23-09-27	PU
PeptiDream Announces Initial Public Offering of RayzeBio and Update on GPC3 Program	23-09-20	AQ
PeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide-Radioisotope Drug Conjugates	23-09-19	BU
PeptiDream Inc. Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide- Radioisotope Drug Conjugates	23-09-19	CI
RayzeBio, Inc. has completed an IPO in the amount of $310.9968 million.	23-09-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News PeptiDream Inc.

Equities

4587

JP3836750004

Summary

Filters